Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
2002855 citationsJoyce O’Shaughnessy, Vladimir Moiseyenko et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Robert Leonard
Since
Specialization
Citations
This map shows the geographic impact of Robert Leonard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Leonard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Leonard more than expected).
This network shows the impact of papers produced by Robert Leonard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Leonard. The network helps show where Robert Leonard may publish in the future.
Co-authorship network of co-authors of Robert Leonard
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Leonard.
A scholar is included among the top collaborators of Robert Leonard based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Robert Leonard. Robert Leonard is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Poole, C. J., Louise Hiller, Helen Howard, et al.. (2006). Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. Breast Cancer Research and Treatment. 100.1 indexed citations
9.
Miles, David, K W Ryder, R.D. Rubens, Robert Leonard, & David Cameron. (2003). Comparison of 'three weekly' (q3w) vs 'four weekly' (q4w) adjuvant CMF chemotherapy in operable breast cancer. Breast Cancer Research and Treatment. 82.3 indexed citations
10.
Vukelja, S., Vladimir Moiseyenko, Robert Leonard, et al.. (2001). Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results. Breast Cancer Research and Treatment. 69(3).6 indexed citations
Eccles, Diana, et al.. (1992). Allele loss on chromosome 11p is associated with poor survival in ovarian cancer.. PubMed. 10(2). 95–9.17 indexed citations
14.
Condie, Alison, et al.. (1991). A familial RB1 mutation detected by the HOT technique is homozygous in a second primary neoplasm.. PubMed. 6(12). 2353–6.19 indexed citations
15.
Chetty, U, et al.. (1985). Breast cancer. BMJ. 290(6471). 855.6–856.1 indexed citations
Bennett, Charles F. & Robert Leonard. (1970). Field experimentation in rural sociology.. Rural Sociology. 35(1). 69–76.1 indexed citations
20.
Leonard, Robert, James K. Skipper, & Powhatan J. Wooldridge. (1967). Small Sample Field Experiments for Evaluating Patient Care. Health Services Research. 2(1). 46.6 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.